Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma

JAMA Oncology

Volumn 4, Issue 1, 2018, Pages 98-101

  Shoushtari, Alexander N ^a,b   Friedman, Claire F ^a,b   Navid Azarbaijani, Pedram ^a,b   Postow, Michael A ^a,b   Callahan, Margaret K ^a,b   Momtaz, Parisa ^a,b   Panageas, Katherine S ^a   Wolchok, Jedd D ^a,b   Chapman, Paul B ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; IPILIMUMAB; MYCOPHENOLIC ACID; NIVOLUMAB; PEMBROLIZUMAB; STEROID; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; AUTOIMMUNE DISEASE; CANCER RADIOTHERAPY; COHORT ANALYSIS; COLITIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MYASTHENIA GRAVIS; PANCREATITIS; PNEUMONIA; PROSPECTIVE STUDY; PRURITUS; RASH; SARCOIDOSIS; SKIN SURGERY; TIME TO TREATMENT; TREATMENT FAILURE; TREATMENT WITHDRAWAL; ADVERSE DRUG REACTION; CLINICAL TRIAL; COMPASSIONATE USE; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; INCIDENCE; MELANOMA; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPASSIONATE USE TRIALS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NIVOLUMAB; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TIME FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 85041185878     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.2391     Document Type: Conference Paper

References (6)

1. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
2. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015.
3. PostowMA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21): 2006-2017.
4. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11): 1558-1568.
5. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol 33. 2016;(18-suppl). doi:10.1200/jco.2015.33.18-suppl.lba1
6. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190-209.